Does Menopausal Hormone Therapy Lower Dementia Risk? Timing and Genetics May Hold the Answer
Emerging research suggests that women who experience longer reproductive spans or who utilize menopausal hormone therapy (MHT) may enjoy enhanced brain health as they age. A study published in the journal *Neurology* on November 4 reveals a connection between prolonged exposure to estrogen and reduced signs of damage to small blood vessels in the brain.
This study is particularly significant given that women represent approximately two-thirds of Alzheimer’s disease cases globally. Researchers found that a longer reproductive life span, particularly later onset of menopause, was linked to an 8% lower risk of exhibiting multiple markers of small vessel disease (SVD), a condition characterized by reduced blood flow to the brain.
The study also explored how genetic factors influence the relationship between hormone therapy and brain health. Findings indicated that women carrying the APOE-ε4 genetic variant, which heightens the risk of Alzheimer’s, showed improved cortical thickness in brain regions susceptible to the disease when using MHT. However, no similar benefits were observed in women without this genetic variant.
The intricate relationship between estrogen and brain health is underscored by these findings. While longer exposure to estrogen may correlate with healthier cognitive aging, researchers caution that MHT has not been definitively proven to prevent Alzheimer’s or dementia.
The research team analyzed data from the Gothenburg H70-1944 Birth Cohort, which included 1,203 individuals born in 1944 in Gothenburg, Sweden. Of these, 352 cisgender women, averaging 70 years old and free of neurological disorders, provided reliable self-reported data regarding their estrogen exposure. This exposure was evaluated based on factors such as the age of first menstruation, age at menopause, type of menopause (surgical or natural), and the use of oral contraceptives and MHT.
Participants underwent brain MRI scans both at the study’s outset and five years later. Results showed that those with longer reproductive spans had a significantly lower risk of SVD. The primary factor contributing to this association was later onset of menopause rather than earlier menstruation.
Experts highlight the importance of understanding estrogen’s role in brain health. Dr. Dung Trinh, an internist and Chief Medical Officer at Healthy Brain Clinic, noted that estrogen influences several brain functions, including the communication between cells and the maintenance of healthy blood vessels. He emphasized that as estrogen levels decline during menopause, the protective effects on the brain may diminish, indicating that starting MHT closer to menopause could be beneficial.
Dr. Sherry Ross, a board-certified OB/GYN, echoed these sentiments. She suggested that initiating hormone therapy earlier during the menopause transition could mitigate cognitive changes, potentially lowering long-term risks for Alzheimer’s disease.
Both experts stress the need for individualized treatment plans for women undergoing menopause. They assert that decisions regarding hormone therapy should consider a woman’s unique symptoms, medical history, and overall health rather than applying a universal approach. Future research may further clarify when and how to best utilize MHT for cognitive health, but for now, the focus remains on tailoring treatments to fit individual needs and circumstances.
